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Summary. Prothrombinase activity was analysed in the
plasma of a series of patients with lupus anticoagulants
(LAC). In the presence of purified PS-PC (20-80/o) vesicles
the prothrombinase activity triggered by kaolin was retarded
by 2-3 min with respect with normal plasma. The maximal
values of prothrombinase activity increased by increasing the
amount of phospholipid vesicles. However, in the plasma of
the patients they were always lower than those of normal
plasma at each phospholipid concentration. Platelet-depen-
dent prothrombinase activity was subsequently investigated.
Again, both a delay in appearance and reduced peak values of
prothrombinase activity were observed in the plasma of the
patients. This inhibition was partially overcome by the
addition of an excess of purified phospholipids. Finally, the
effect of LAC IgG on platelet rich plasma-dependent pro-
thrombinase activity was investigated. The main effect
observed was a delay of the peak time of prothrombinase
activity, while the maximal peaks were a,ffected only by one
IgG preparation. We conclude that LAC antibodies can react
with both purified negatively-charged phospholipids and
platelet procoagulant phospholipids and inhibit prothrombi-
nase activity in a similar way in both cases.
Lupus anticoagulants (LAC) are acquired inhibitors of
coagulation described for the first time in 1952 by Conley &
Hartmann in two patients suffering from systemic lupus
erythematosus (SLE).
LAC are immunoglobulins of the IgG and/or (less fre-
quently) IgM class, which prolong the clotting tests measur-
ing the activated partial thromboplastin time (aPTI) (Mueh
et al,1.980).
The immunological nature and the mechanism of action of
LAC have been extensively studied by the group of Shapiro
(Thiagarajan et al, 1980; Pengo et aI, 1987). The purified
immunoglobulins react against negatively-charged phospho-
Iipids (i.e. phosphatidylserine, phosphatidic acid, phosphati-
dylinositol and cardiolipin) and they are able to inhibit the
binding of factor X and prothrombin to the phospholipid
surface, thereby accounting for the prolongation ofphospho-
lipid-dependent clotting tests.
Phospholipids are structural components of the platelet
membrane. The negatively-charged phospholipids are almost
exclusively located in the inner part of the membrane of
Correspondence: Dr Monica Galli, Department of Haematology,
Ospedali Riuniti, Largo Baroni 1,24100 Bergamo, Italy.
resting platelets, but they are exposed on the outer surface
upon platelet activation (Bevers et aI, 1982). This transbi-
Iayer rearrangement has been called 'flip-flop' and is respon-
sible for the procoagulant properties of platelets in factor X
and prothrombin activation (Rosing et aI, 1985).It seems to
be likely that LAC antibodies, by binding to the negatively-
charged phospholipids, can interfere with the procoagulant
activity of activated platelets. Actually, this has been demon-
strated only in one case by Dahlback et aI (1983), while in
their original work Thiagarajan et aI (1980) were not able to
show any inhibitory effect of the LAC immunoglobulin on the
binding of factor Xa to platelets. Furthermore, other authors
developed assays for the diagnosis ofLAC, based on the ability
of platelets to normalize the prolonged clotting tests (Firkin et
aI, 1978; Triplett et al, 7983). Thus, it was suggested that
platelets can by-pass the presence of the acquired anticoagu-
lants. In contrast, it has been suggested that I"AC antibodies
can react with platelets, because thrombocytopenia (Harris et
aI, 198 5), 'ex vivo' platelet activation (G aIk et aL,1988) and 
'in
vitro' platelet aggregation abnormalities (Cohen et aI, 1986)
have been reported in patients with the antiphospholipid
antibodies. Moreover, it has been observed that commercially
available phospholipid reagents for clotting tests, used to
detect LAC inhibitors, show a large variation of sensitivity to
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the antibodies due to the variations in both the concentra-
tions and the nature of the phospholipid in the preparation
(Mannucci el aI,7979\. These data led to the hypothesis that
LAC antibodies are heterogenous.
To assess whether there is a general reactivity of LAC
immunoglobulins towards negatively-charged phospholipids
from different sources, we studied the plasma of a series of
patients with these antibodies. In particular, we evaluated
the inhibitory effect of the acquired anticoagulants on the
prothrombinase activity induced by platelets and by purified
negatively-charged phospholipids vesicles. We used a com-
puter assisted method, recently developed in this laboratory
(Hemker et aI, 1986\, which allowed us to measure the
prothrombinase activity in plasma independently of throm-
bin breakdown by antiproteases. Thus, we could approach
closely the 'in vivo' situation. We demonstrate here that the
inhibition of prothrombinase activity by LAC antibodies is
more dependent on the amount of negatively-charged phos-
pholipids present in the system than on the source of
procoagulant surface.
MATERIALS AND METHODS
Patients. Nine patients with LAC were investigated, two
males and seven females, 27-60 years old. Details of the
clinical history are given in Table L SLE was diagnosed
according to the criteria established by the American Rheu-
matism Association (Tan et al, 1982). Both venous and
arterial thrombosis were diagnosed by angiography.
A control group was established of 1O apparently healthy
subjects.
Diagnosis of LAC. Blood was collected in trisodium citrate (9
volumes of blood to 1 volume of 0'13 lvr trisodium citrate) and
centrifuged at 4000 g for 20 min to obtain platelet poor
plasma (PPP). PPP was stored at - 8O"C until use. Plasma of
10 normal individuals was pooled and used as a reference in
the coagulation assays. The following tests were used for the
diagnosis of LAC: activated partial thromboplastin time
(aPTT) (Activated Thrombofax, Ortho Diagnostic, Raritan,
N.I., U.S.A.), kaolin clotting time (KCT) (Exner ef aI, 1978)
and diluted Russel viper venom time (RVV) (Thiagarajan et
aI, 1986) (Wellcome Reagents Beckenam, England), before
and after 1 :1 mixture of patients plasma with normal pooled
plasma, tissue thromboplastin inhibition test (TTI), using
Simplastin (General Diagnostics, Warner Lambert Co., Morris
Plains, N.J.,  U.S.A.) di luted 1:50 and 1:500 with sal ine
(Schleider et aI, 797 6).
Preparation ol IgG immunoglobulins. IgG immunoglobulins
from seven patients and four normal subjects were isolated.
Serum (20 ml) was dialysed against O'02 nr K2HPO4, pH 8'0
at 4oC overnight. Then it was applied to a column of DEAE
Affi-Gel Blue (Bio Rad, Richmond, Calif, U.S.A.) equilibrated
with the same buffer. The effluent immunoglobulins were
concentrated by Amicon ultrafiltration, using a PM 1O
membrane (Amicon Corp, Lexington, Mass., U.S.A.). Protein
concentration was established by a nephelometric method
using a Beckman system (Auto ICS, Beckman Instr., Fuller-
ton, Calif., U.S.A.). Immunoelectrophoresis was performed
with human antisera specific for total immunoglobulins, IgG,
IgM and light chains (Heldna Laboratories, Beaumont, Texas,
u.s.A.).
Patients IgG were studied for their anticoagulant activity
by adding 0'05 ml of IgG to 0'05 ml of normal pooled PPP in
a KCT assay. Anticoagulant activity was considered to be
present, when the clotting time was at least 1'5 times that of
the control, i.e. with IgG from normal subjects.
Measurement ol prothrombinase activity in plasma. For the
measurement prothrombinase activity in plasma the pro-
cedure of Hemker et aI (1986) was used. Briefly, 0'24 ml of
normal pooled or patients PPP were incubated at 37"C for 5
min with 0'06 ml of Tris buffer (0'1 tu NaCl, 0'05 u Tris, pH
7'35) containing kaolin (0'28 mg/ml) and various concen-
trations of phospholipid vesicles (80"/e phosphatidylcholine,
PC, and 20olo ofphosphatidylserine, PS), prepared according
to Rosing et aI (1983) or with O'06 ml of different concentra-
tions of washed platelet suspensions, prepared according to
Rosing et a.l (1985). In some experiments, 40 pu of purified
PS/PC vesicles were added to PPP at the same time as the
washed platelets. Thrombin generation was started by the
addition of 0'06 ml of 0'1 u CaCIz, pH 7'35. At fixed time
intervals 0'01 ml aliquots of the incubation mixture were
subsampled into tubes containing 0'465 ml of a Tris-EDTA
buffer (0'1 lr  NaCl, 0'05 u Tris, 0'02 rt  EDTA, O'O5%
ovalbumin, pH7'9) and 0'025 ml of a 0'004 u solution of
chromogenic substrate 52238 (Kabi Vitrum, Stockholm,
Sweden) at 37"C. The subsampling tubes were incubated for
2 min at 37oC and then, by addition of 0'3 ml of 50% acetic
acid, the reaction was stopped. The amidolytic activity was
measured at 405 nm wavelength in a spectrophotometer
(LKB-UItrospec., Bromma, Sweden). From the change in
absorbance and the time interval between subsampling and
stopping the thrombin amidolytic activity was calculated.
Thrombin concentration was calculated using a calibration
curve made with active-site titrated human thrombin.
Thrombin breakdown constants were also determined
according to Hemker et aI (1986). Briefly, the same mixture
as for thrombin generation curves was used, but with a
volume of 0'048 ml of Tris-buffer mixture or platelet
suspension instead of 0'06 ml. Two minutes after the
thrombin peak 0'012 ml of Soybean trypsin inhibitor (SBTI)
(10 mg/ml) (Sigma, StLouis, Mass., U.S.A.)were added to the
reaction mixture, so as to stop prothrombinase activiby. At
variable intervals after the addition of SBTI, 0'01 ml aliquots
were subsampled into cuvettes by the use of a time recording
pipette. The cuvettes were further treated as described for the
thrombin generation test. The overall decay constant is the
sum of the a2 macroglobulin (azM) dependent constant (kz)
and the non-d2M-dependent constant (kr), mainly due to
antithrombin III. From the ratio of the amount of prothrom-
bin consumed during the experiment (i.e. the total amount of
thrombin formed) and the amount taken up by azM,
determined using staphylocoagulase (50 nm) (Hendrix et a/,
1983), kr and k2 were determined separately (for details see
Hemker et al, 1986).
Prothrombinase activity (expressed in nu Ila/min) was
calculated by a computer using the thrombin generation data
and the experimentally determined decay constants kr and kz
of endogenous thrombin (Hemker et al, 1986).
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Table I. Clinical and laboratory data in nine patients with LAC
Patient Age Sex Clinical rernarks
TTI
APTT APTT l:1 KCT KCT 1: I  1/50 1/500
TYPe of
LAC
RVV RVV 1:1 ant ibodY
IgG
IgG
IgG
IgG
IgG
IgG
IgG
52
60
73
1 1 9
109
601 6 8
9 6
126
1 8 6
9 8
178
3 5
J O
1 0
R.A.
G.S.
c.L.
D.S.
M.S.
z.R.
T.A.
T.N.
B.A.
Controls (10)
3 0 F
3 3 M
2 7 F
3 1  F
6 0 M
4 l F
2 9 F
3 6 F
5 6 F
SLE; transient
ischaemic attacks
Peripheral arterial
thrombosis
Recurrent abortions;
deep venous thrombosis
SI,E
Deep venous thrombosis
Cerebral thrombosis
Repeated abortions; SLE
Repeated abortions; SLE
3 6
+t)
40
48
3 5
7 5
) a
60
3 7
3 6
66
30
A )
196
1 3 0  1 1 3
1 0 9  1 1 1
1 1 0  9 7
r 2 7  1 0 0
140 127
64-7 5
6 1  1 5 1
to2 252 65
43 85  63
59 r32 41
35-40 63-77 25-30
46
48
3 8
26-30
All results are expressed in seconds.
Effect of LAC IgG on prothrombinase activity in normal platelet
rich plasma. Platelet rich plasma (PRP) was obtained by
centrifugation at 77O g for 10 min of freshly drawn citrated
normal blood. Platelet concentration was determined with a
thrombocounter (Coulter Counter Electronics, Hialeah, FIa.,
U.S.A.) and adjusted at 300 x 10e platelets/l with autologous
PPP.
Thrombin generation and prothrombinase activity were
determined according to the method of B6guin et al (1989).
The samples consisted of O'24 ml of PRP and 0'06 ml of
normal pooled or patients IgG at various concentrations.
After 5 min of incubation at 3 7oC the thrombin generation
was started by the addition of 0'06 ml of 0'1 rvr CaCl2 or 0'06
ml of a 1:600 dilution in 0'1 u CaCIz of human brain
thromboplastin, prepared by a modification of the method of
Owren & Aas (19 5 1) and prewarmed for I h at 3 7'C' At fixed
time intervals 0'01 ml aliquots of the incubation mixture
were subsampled into tubes containing 0'465 ml of Tris-
EDTA buffer and 0'02 5 ml of a 0'004 lt solution of S 2238 at
37"C. Ttre subsampling tubes were incubated for 2 min at
3 7"C and then, by addition of 0'3 ml of 5O% acetic acid, the
reaction was stopped. The amidolytic activity was tested as
above described.
In order to overcome the effect of platelet ageing, the
experiments were carried out within 2 h from the venipunc-
ture. Prothrombinase activity was calculated as above
described.
RESULTS
Coagulation studies and characterization of LAC inhibitors
The aPTT, KCT and dilute RW clotting times in all the nine
patients exceeded those of the normal group and no correc-
tion was noted on mixing 1:1 patients and normal PPP. TTI
was also abnormal in all the cases (Table I).
Immunoglobulins with LAC activity were found to be IgG
in the seven patients in whom the identification of the
inhibitor was performed (Table I).
200
200
0
5  1 0
Ti  me (m in)
Fig 1. Prothrombinase activity (nru Ila/min) in normal pooled plasma
(upper panel) and in the plasma of patient R.A. (lower panel) induced
by the following concentrations of PS/PC vesicles: a- - -4, O'5 pM;
O- - -o, 1 1ru; a-a, 5 pu; o-o, 10 Pl't.
Eflect of phospholipid vesicles and normal platelets on prothrombi-
nase activity in PPP
Phospholipid-dependent prothrombinase activity was eva-
luated in normal and in eight patients' PPP. Reactions were
studied in the intrinsic pathway, using procoagulant phos-
pholipid vesicles (PS/PC) at the concentrations given in Fig I
and Table IL The course of prothrombinase activity was
=
q)
o
c
o.
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Table II. Maximal amounts of prothrombinase activities in patients
and normal pooled PPP in the presence of phospholipid vesicles or
washed normal platelets
PS/PC (pu)
Washed
platelets
( x 10e/l)
Table III. Thrombin breakdown constants
of normal platelet poor plasma (PPP),
platelet rich plasma (PRP) and reconsti-
tuted PRP. k2 is the d2 macroglobulin
dependent constant, k1 the non d.z mac-
roglobulin dependent constant.
k2 k1
lmln -) tmln 
-.1
PPP 0 .13  0 .78
PRP 0 '13  0 .85
Reconstituted PRP* 0'13 0'88
* Washed platelets resuspended in auto-
logous PPP at a final concentration of
200 x 10e/1.
120
100 200
PLATELETS (x1O,/L)
Fig 2. Concentration effect of washed normal platelets on the
prothrombinase activity (nu Ila/min) in normal pooled plasma.
thrombin breakdown constants were not influenced by the
presence ofplatelets. Thus, the values ofkl and k: measured
in PPP were also used to calculate platelet-dependent
prothrombinase activity. A calibration curve was obtained by
incubating normal PPP with increasing concentrations of
washed platelets (from 0 to 200 x 1Oe/l). As depictedin Fig 2,
prothrombinase activity increased with the platelet number.
Platelet-dependent prothrombinase activity in normal and
eight patients' PPP was subsequently evaluated in the
presence of lO0 and 200 x 10e platelets/I. Clotting reactions
were started by the addition of CaClz. In these conditions the
maximal prothrombinase activity was reached after 8-11
min with both 100 and 200 x 10e platelets/l in normal PPP
(Fig 3). Also the peak amount of prothrombinase activity did
not change significantly with the number of platelets (Table
r).
In the plasma of the patients the maximal amounts of
200r001 00 . 5
R.A.
G .S .
C.L.
D.S.
M.S.
z.R.
T.A.
T.N.
B.A.
6 5
ND*
76
104
r 0 9
6 5
73
ND
ND
9 5
1 1 3
1 1 5
177
204
9 7
r23
ND
2 8
200
z )  |
t \ z
348
376
463
305
306
ND
54
4 3 3
3 1 0  4 4
ND 37
4 1 5  5 3
352 55
ND 61
397 52
384 65
ND ND
7 3 9
5 3 8  8 1
5 3
64
62
7 5
ro4
a 5
80
ND
20
9 1Normal 119
pooled PPP
* ND: not done. The data are expressed in nu llalmin.
calculated from the thrombin generation curves by means of
the breakdown constants of thrombin. kr * kz was measured
in normal and in five patients PPP (R.A., C.L., M.S., 2.R.,
T.A.). No differences were found: a kr + kz of I'04 min- t and a
mean value of 1'03 min 1 (range 0'99-1'066 min 1) were
observed in normal PPP and in patients PPP, respectively.
AIso kr and k2 were found similar in normal PPP (k1 :O'78
min-r, k2:0.26 min-1) and in the PPP of the two patients
(C.L., M.S.) in which this evaluation was carried out
(k i :0 '73-0 '84  min-1 ,  k2 :O '22-O '26  min-1) .  We con-
cluded that the thrombin inactivation system did not signifi-
cantly differ in the group of plasmas that we studied and we
used the mean values throughout kr:0'78 min-1, k2:0'25
min 1.
The peak amounts of phospholipid-dependent prothrombi-
nase activity in normal PPP were reached at 1-2 min and
they were proportional to the concentration ofPS/PC vesicles
(Fig 1 and Table II). In the PPP of the patients the
prothrombinase peaks were reached at 5-3 min: this delay
was shortened, although never completely normalized, by
increasing the phospholipid concentration. Also the pro-
thrombinase activities increased by increasing the PS/PC
amount; however, in all but one case (M.S.) they were found
Iower than that of the normal PPP at each phospholipid value
(Fig 1 and Tabte II).
In order to assess differences in the reactivity of LAC
inhibitors towards phospholipids of different sources, the
prothrombinase activity was subsequently evaluated in the
presence of normal platelets as the source of procoagulant
phospholipids. The prothrombinase activity was calculated
from the thrombin generation data by means of the break-
down constants of thrombin. As a control, kr and k2 were
measured in normal PPP. PRP and reconstituted PRP
(washed platelets resuspended in autologous PPP at a final
number of 200 x 10e/l). As depicted in Table III, the values of
c
E
= 8 0
c
U
u)
z
tD
2 a o
o
F
E
1 0 0
T I M E  ( m i n )
Fig 3. Prothrombinase activity (nu [Ia/min) induced by 200 x IOe
washed normal platelet/l in normal pooled plasma (o) and in the
plasma of patient R.A. (l).
prothrombinase activity were reached later and they were
found lower than in normal plasma. The differences were
more pronounced in the presence of 100 x 10e platelets/I. In
particular, the peak amounts of prothrombinase activity
were observed at 10-20 min with 100 x 1Oe platelets/l and
at 9-16 min in the presence of 200 x 10e platelets/I. The
values of prothrombinase are given in Table IL When an
excess of PS/PC vesicles (a0 pu) was added at the same time
as 100 x 10e washed platelets/l to the plasmas of three
patients (R.A., G.S., B.A.) prothrombinase activity was
completely normalized in two cases (R.A., G.S.) and partially
normalized in the third one (patient B.A.) (data not shown).
Eflect of LAC IgG on prothrombinase activity in normal PRP
The maximal prothrombinase activity was reached at 8-11
min when normal PRP was mixed with 10 mg/ml of normal
pooled IgG and coagulation was initiated by the addition of
CaClz. The peak value of prothrombinase activity was
advanced to 6-8 min in the presence of a high dilution of
thromboplastin (1 :3600 finat). No significant differences
were found in the maximal prothrombinase activity in these
two experiments. In fact, the mean values were 114 nu IIa
min-r (range 94-152) and 95 nu IIa min 1 (range 80-124)
in the presence of CaCIz and calcium plus thromboplastin,
respectively. The main effect exerted by tAC IgG on normal
PRP was a delay of the peak time of prothrombinase activity.
When the clotting reaction was started by CaCl2 the peak was
reached at 11-18 min. In the presence of thromboplastin the
delay was reduced in all cases (range 4-15 min) and
completely normalizedin two of them (patients C.L. andZ.R.).
These results were obtained using 10 mg/ml of IgG with LAC
activity. In one case only (patient B.A.)concentrations of IgG
higher than 1 mg/ml completely abolished the prothrombi-
nase activit5r. From Fig 4 it appears that the peak amount was
reduced and the lag time was increased by increasing
amounts of this patient's IgG. In the other cases the delay of
the peak time of prothrombinase activity was almost com-
pletely normalized when the concentration of LAC IgG was
decreased to 5 mg/ml (data not shown). LAC immunoglobu-
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1 0 0
5  1 5  2 5
T i m e  ( m i n )
Fig 4. Prothrombinase activity (nu lla/min) in platelet-rich
plasma in the presence of normal and LAC IgG. O, Normal IgG
(10 mglml); l,IgG of patientB.A. (0.5 mglml); o,IgG ofpatientB.A.
(0'1 me/ml).
lins were, on the contrary, not able to interfere with the
maximal velocity of prothrombinase activity in PRP: the
values were close to those observed when PRP was mixed
with normal IgG (data not shown).
DISCUSSION
Since (partially) purified preparations of LAC immunoglobu-
lins have been available, the mechanism of action of these
acquired anticoagulants has undergone intensive investiga-
t ion (Thiagaraj an et aI,1 980; Dahlback et a\,1983; Pengo et
al, 1987). They were shown to interfere with the binding of
factor X and prothrombin to negatively-charged phospholi-
pid surfaces (Thiagarajan et aI, I98O; Pengo et al, 7987).
However, these and other studies did not clarify the interac-
tion of LAC antibodies with platelet procoagulant phospholi-
pids (Firkin et aI, 1978: Dahlback et al, 7983: Triplett et aI,
1983; Thiagarajan et aI, 1987).
In the present work we wanted to investigate the phospho-
lipid and platelet-dependent prothrombinase activity directly
in the plasma of patients with LAC.
We first determined the prothrombinase activity in plasma
of the patients activated via the intrinsic pathway, using
different concentrations ofPS/PC vesicles as a procoagulant
surface. We observed that both the rate of development and
the peak amount of prothrombinase activity were reduced in
the plasma of the patients. This phenomenon was clearly
dependent on the amount of phospholipid in the system, since
a partial normalization of the prothrombinase activity was
reached by increasing the concentration ofPS/PC vesicles.
By binding to the phospholipid surface, LAC antibodies
may inhibit the prothrombinase activity by hampering the
assembly of the prothrombin activating complex (factor Xa,
factor Va, phospholipid and calcium) on the procoagulant
surface or by hindering the binding of prothrombin to an
otherwise normal prothrombinase complex. The interference
of LAC immunoglobulins with the binding of factor Xa and
prothrombin to purified phospholipids has already been
E
=
0)
B  s o
E
E
o
=
ut
a
i s o
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o
G
F
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demonstrated (Thiagarajan et al, 1980). We think therefore
that the observed reduction of the peak amount of the
prothrombinase activity is due to both deficient formation of
the prothrombinase complex and poor substrate binding.
Another possible mechanism of action of LAC antibodies
can be the inhibition of the generation of one or more of the
constituents of the prothrombin activating complex. In fact,
the acquired anticoagulants, by a lower rate of conversion of
prothrombin into thrombin, may inhibit the feedback acti-
vation of factors V or VIII by thrombin.
LAC antibodies can also interfere with factor X activation.
In fact the factor X activating complex (factor IXa, factor
VIIIa, phospholipid and calcium) resembles the prothrombin
activating complex so much that the phospholipid binding
antibody presumably inhibits the one as much as the other.
This is probably the cause for the observed delay of appear-
ance of the prothrombinase activity. Further studies will have
to elucidate the extent of this inhibition.
The influence of LAC on platelet-dependent prothrombi-
nase activity was also investigated. We demonstrated that
platelets do not significantly influence the breakdovvn con-
stants (kr and k2) of thrombin in plasma (see Table III). It has
been observed that activated platelets increase the rate of
thrombin inhibition by AT III (Jesty, 1985). We did not
observe a significant effect. It is noteworthy that no platelet
product responsible for the increase of thrombin inhibition
has as yet been identifiec.
We found that prothrombinase activity was also affected in
plasma of the patients when washed normal platelets were
used as procoagulant surface. Recently, B6guin et al (1989)
demonstrated the existence of a feedback activation of
platelets by the small amounts of thrombin formed in PRP in
the early stages of coagulation triggered by tiny amounts of
thromboplastin; this makes platelet procoagulant phospholi-
pids available to stimulate a burst of thrombin formation.
LAC antibodies, by binding to the exposed negatively-
charged platelet phospholipids, hamper this feedback acti-
vation, thus accounting for both the delay in the appearance
and the reduction of the peak levels of the prothrombinase
activity. As expected from the observed correlation between
the number of platelets and prothrombinase activity (see Fig
2), this inhibition of platelet-dependent prothrombinase
activity was more obvious at a low platelet number. More-
over, it was (partially) overcome by the addition of an excess
of phospholipids, thus suggesting that the amount of nega-
tively-charged phospholipid more than its source imports for
the expression ofthe anticoagulant effect ofLAC antibodies.
The correlation observed in PRP between the delay of
appearance of prothrombinase activity and the amount of
LAC IgG in the presence of different triggers of platelet
activation supports this view. Unlike the patients' plasma, the
purified LAC immunoglobulins were not able to inhibit the
maximal level of platelet-dependent prothrombinase activity.
This difference might be due to a loss of specific antibodies
during the purification procedure, since it had been found
that polyclonal LAC IgG accounts for no more than the O'2olo
of the whole IgG fractions (Pengo et al, 1987). Moreover
protein(s) other than IgG might take part in the inhibitory
process in the plasma of the patients (Exner et aI' 1978).
In conclusion, our results indicate that LAC antibodies are
able in plasma to react against procoagulant phospholipids
from both platelets and extraneous sources. This reactivity
depends more on the amount of phospholipids present in the
system, than on their nature. Unlike Thiagaraian et aI
(1980), but in accordance with Dahlback et al (1983)' we
found no fundamental difference between the action of the
inhibitor on platelet-mediated prothrombinase and on pro-
thrombinase constituted with PS/PC vesicles. We do not
exclude the possibility that patients may differ in this respect.
In that case the patient studied by Thiagarajan et al seems to
be an exception as in our series all nine patients reacted in the
same way as the Dahlback patient.
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